Summary: A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.

Top Publications

  1. Mackey A, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-8 pubmed
  2. Clement C, Rapport F, Seagrove A, Alrubaiy L, Williams J. Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. BMJ Open. 2017;7:e014512 pubmed publisher
    Insight into healthcare professionals' views and experiences of the use of ciclosporin and infliximab as salvage therapies for acute ulcerative colitis (UC) and how this may affect participation in a comparison trial is lacking...
  3. Ward M. Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care. Arthritis Care Res (Hoboken). 2010;62:293-5 pubmed publisher
  4. Keersmaekers T, Claes K, Kuypers D, de Vlam K, Verschueren P, Westhovens R. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis. 2009;68:759-61 pubmed publisher
  5. Singh J, Hossain A, Mudano A, Tanjong Ghogomu E, Suarez Almazor M, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657 pubmed publisher
    ..the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (MTX)/other DMARDs) in ..
  6. Jørgensen K, Olsen I, Goll G, Lorentzen M, Bolstad N, Haavardsholm E, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304-2316 pubmed publisher
    ..The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity...
  7. Vultaggio A, Nencini F, Pratesi S, Cammelli D, Totaro M, Romagnani S, et al. IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients. J Immunol. 2017;199:1283-1289 pubmed publisher
    b>Infliximab (IFX) is a chimeric mAb that can lead to the appearance of anti-drug Abs. Recent research has identified the presence of circulating IFX-specific T cells in treated patients...
  8. Durham L, Taams L, Kirkham B. Psoriatic arthritis. Br J Hosp Med (Lond). 2016;77:C102-8 pubmed publisher
  9. Jiang Y, Lin O, Sinha S. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci. 2017;62:1597-1606 pubmed publisher
    ..The majority of providers are either uncertain about or actively avoid use of anti-TNF? medications for those with HF. The risks and benefits of anti-TNF? use in HF patients must be investigated further. ..

More Information


  1. Maharshak N, Plevy S. A Crohn's disease patient who does not respond to infliximab: what is next?. Clin Gastroenterol Hepatol. 2011;9:1033-8 pubmed publisher
  2. . Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56:135-58 pubmed publisher
  3. Li T, Liu Y, Xu H. Successful treatment of infliximab in a patient with scleroderma: a case report. Medicine (Baltimore). 2017;96:e6737 pubmed publisher
    ..Here we report a case with a 2-year history of SSc who was effectively treated with infliximab in our clinic. The patient manifested skin thickening, chest tightness and arthralgia...
  4. . Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683-6 pubmed a potential adverse reaction from treatment with the tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira); the three products are labeled accordingly...
  5. Chung J, Rosenbach M. Extensive cutaneous sarcoidosis and coexistant Crohn disease with dual response to infliximab: case report and review of the literature. Dermatol Online J. 2014;21: pubmed
    ..and CD involving the terminal ileum, whose skin and gastrointestinal symptoms improved dramatically with infliximab treatment (5mg/kg on weeks 0, 2, 6, then every 8 weeks)...
  6. Vermeer M, Kuper H, Bernelot Moens H, Hoekstra M, Posthumus M, van Riel P, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14:R254 pubmed publisher
    ..The recommendations regarding T2T were successfully implemented and high adherence was observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice. ..
  7. Fischer M, Campbell S, Calley C, Helper D, Chiorean M, Fadda H. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci. 2017;62:3131-3137 pubmed publisher
    Usefulness of thiopurine and scheduled infliximab combination therapy in non-immunomodulator (IM)-naïve Crohn's disease (CD) patients and the optimal length of dual therapy are still debated.
  8. Schneider A, Hossain I, VanderMolen J, Nicol K. Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review. Complement Ther Med. 2017;33:32-38 pubmed publisher
    ..Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers. ..
  9. Vergou T, Moustou A, Maniateas A, Stratigos A, Katsambas A, Antoniou C. Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis. Int J Dermatol. 2010;49:1215-7 pubmed publisher
  10. Bader L, Solberg S, Kaada S, Bolstad N, Warren D, Gavasso S, et al. Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories. Scand J Immunol. 2017;86:165-170 pubmed publisher
    ..We have analysed infliximab drug levels and antidrug antibodies in 107 patient samples using enzyme-linked immunoassays (ELISA), ..
  11. Hwang S, Yoo H, Yoon M, Park H. Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis. Ann Allergy Asthma Immunol. 2014;112:393-4 pubmed publisher
  12. Dignass A, Van Assche G, Lindsay J, Lemann M, Soderholm J, Colombel J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4:28-62 pubmed publisher
  13. Danese S, Fiorino G, Peyrin Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704-11 pubmed publisher
    ..trials that were rated as low risk of bias and showed that all biological agents (adalimumab, golimumab, infliximab, and vedolizumab) resulted in more clinical responses, clinical remissions, and mucosal healings than placebo ..
  14. Xu J, Lin H, Feng X, Tang M, Shen J, Ran Z. Different therapeutic approaches on quality of life in patients with inflammatory bowel disease. BMC Gastroenterol. 2014;14:199 pubmed publisher
    ..Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of ..
  15. Desbois A, Vallet H, Domont F, Comarmond C, Cacoub P, Saadoun D. Management of severe complications in Behçet's disease with TNF inhibitors. Expert Opin Biol Ther. 2017;17:853-859 pubmed publisher
    ..Experts in the field do recommend the use of anti-TNF agents (either infliximab or adalimumab) as a first-line therapy in severe posterior uveitis in BD and now use anti-TNF? treatment in BD-..
  16. Heidelberger V, Ingen Housz Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, et al. Efficacy and Tolerance of Anti-Tumor Necrosis Factor ? Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol. 2017;153:681-685 pubmed publisher
    ..Most patients received infliximab (n?=?40 [87%]), with systemic steroids in 28 cases (61%) and immunosuppressants in 32 cases (69.5%)...
  17. Cavallaro F, Duca L, Pisani L, Rigolini R, Spina L, Tontini G, et al. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Can J Gastroenterol Hepatol. 2017;2017:6843976 pubmed publisher
    ..This effect appears to be related to the modulation of the cytokine network and specifically IL-6 leading to a relevant decrease of hepcidin, a master regulator of ACD. ..
  18. Glintborg B, Sørensen I, Loft A, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426-1431 pubmed publisher
    According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial ..
  19. Gupta Ganguli M, Cox K, Means B, Gerling I, Solomon S. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes?. Diabetes Care. 2011;34:e121 pubmed publisher
  20. Schoffelen T, Kampschreur L, van Roeden S, Wever P, den Broeder A, Nabuurs Franssen M, et al. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNF? therapy. Ann Rheum Dis. 2014;73:1436-8 pubmed publisher
  21. Longin O, van de Langemheen H, Liskamp R. An orthogonally protected CycloTriVeratrylene (CTV) as a highly pre-organized molecular scaffold for subsequent ligation of different cyclic peptides towards protein mimics. Bioorg Med Chem. 2017;25:5008-5015 pubmed publisher
    ..of medium-sized protein mimics is illustrated by the synthesis of a paratope mimic of the monoclonal antibody Infliximab (Remicade®) and provides access to a range of highly pre-organized molecular constructs bearing three different ..
  22. Liu C, Fonken L, Wang A, Maiseyeu A, Bai Y, Wang T, et al. Central IKKβ inhibition prevents air pollution mediated peripheral inflammation and exaggeration of type II diabetes. Part Fibre Toxicol. 2014;11:53 pubmed publisher
    ..system, or administered intra-cerebroventricular with either IKKβ inhibitor (IMD-0354) or TNFα antibody (infliximab) for 4-5 weeks simultaneously with PM2.5 exposure...
  23. MacKenzie A. Balancing the benefits and risks of empirical antibiotics for sinusitis: a teachable moment. JAMA Intern Med. 2014;174:1221-2 pubmed publisher
  24. Günther C, Aringer M, Lochno M, Kämmerer E, Bauer A, Wozel G, et al. TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. Acta Derm Venereol. 2012;92:401-3 pubmed publisher
  25. Peake S, Bernardo D, Mann E, Al Hassi H, Knight S, Hart A. Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: a novel mechanism for paradoxical inflammation?. J Crohns Colitis. 2013;7:765-7 pubmed publisher
  26. Fischer T. [Pharmacological therapy of age-related macular degeneration based on etiopathogenesis]. Orv Hetil. 2015;156:1847-58 pubmed publisher
    ..However, randomised prospective clinical trials are still needed to elucidate the potential role of these drug treatments in the prevention and treatment of age-related macular degeneration. ..
  27. Joshi N, Nautiyal A, Walton T. Infliximab therapy for inflammatory discitis in ankylosing spondylitis. J Clin Rheumatol. 2012;18:109-10 pubmed publisher
  28. Bergstra S, Landewe R, Huizinga T, Allaart C. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Rheumatology (Oxford). 2017;56:1721-1728 pubmed publisher
    ..who have continuous low disease activity and are on MTX with or without initial combination therapy with infliximab or prednisone and SSZ...
  29. Paschalis E, Zhou C, Lei F, Scott N, Kapoulea V, Robert M, et al. Mechanisms of Retinal Damage after Ocular Alkali Burns. Am J Pathol. 2017;187:1327-1342 pubmed publisher
    ..Intraocular pressure elevation was not observed in experimental alkali burns. These findings illuminate the mechanism by which alkali burns cause retinal damage and may have importance in designing therapies for retinal protection. ..
  30. Matsumura K, Nakase H, Yamamoto S, Yoshino T, Takeda Y, Kasahara K, et al. Modulation of the Th1/Th2 balance by infliximab improves hyperthyroidism associated with a flare-up of ulcerative colitis. Inflamm Bowel Dis. 2009;15:967-8 pubmed publisher
  31. Bunchuk N, Rumiantseva O, Loginova E, Bochkova A, Storozhakov G, Ettinger O, et al. [The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study]. Ter Arkh. 2010;82:41-6 pubmed
    To evaluate the efficacy and tolerability of the anti-tumor necrosis factor-alpha infliximab in patients with active ankylosing spondylitis (AS) in a 54-week multicenter open-label study...
  32. Panaccione R, Ghosh S, Middleton S, Márquez J, Scott B, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3 pubmed
    The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously...
  33. Gaddy J, Khan Z, Chaser B, Scofield R. Whipple's disease diagnosis following the use of TNF-? blockade. Rheumatology (Oxford). 2012;51:946 pubmed publisher
  34. Dischereit G, Tarner I, Müller Ladner U, Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol. 2013;32:377-81 pubmed publisher
  35. Miyake T, Ogawa E, Mikoshiba A, Kobayashi A, Hosoe H, Kashiwabara S, et al. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci. 2012;68:199-202 pubmed publisher
  36. Akitake R, Nakase H, Tamaoki M, Ueno S, Mikami S, Chiba T. Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis. Dig Dis Sci. 2010;55:1781-4 pubmed publisher
  37. Wong U, Cross R. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol. 2017;13:1039-1046 pubmed publisher
    Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management challenge in clinical practice...
  38. Turina M, Yeremenko N, Paramarta J, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16:413 pubmed publisher
    ..immunosorbent assay (ELISA) in healthy controls (n?=?20) and SpA patients before and after 2 weeks of infliximab (n?=?18) or placebo (n?=?19) treatment in cohort 1. Clinical outcome was evaluated at week 12...
  39. Klingberg E, Strid H, Ståhl A, Deminger A, Carlsten H, Ohman L, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19:21 pubmed publisher
    ..We propose that fecal calprotectin may be a potential biomarker to identify patients with AS at risk of developing IBD. identifier: NCT00858819 . Registered 9 March 2009. Last updated 28 May 2015. ..
  40. Smits L, Grelack A, Derikx L, de Jong D, van Esch A, Boshuizen R, et al. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62:3117-3122 pubmed publisher
    Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients...
  41. Null K, Xu Y, Pasquale M, Su C, Marren A, Harnett J, et al. Ulcerative Colitis Treatment Patterns and Cost of Care. Value Health. 2017;20:752-761 pubmed publisher care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC)...
  42. Uhlig T, Goll G. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49-iv62 pubmed publisher
    ..Additional ongoing studies and registries may help to optimize the process of switching, and different funding models are examining the optimal mechanisms to ensure effective uptake of these new treatments. ..
  43. Mizoshita T, Katano T, Tanida S, Hirano A, Miyaki T, Ozeki K, et al. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017;96:e7800 pubmed publisher
    There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC)...
  44. Santos J, Malaguti C, Lucca F, Cabalzar A, Ribeiro T, Gaburri P, et al. Impact of biological therapy on body composition of patients with Chron's disease. Rev Assoc Med Bras (1992). 2017;63:407-413 pubmed publisher
    ..assessment by bioelectrical impedance method in patients with moderate to severe CD undergoing treatment with infliximab. The main outcome was the body composition before and after 6 months of anti-TNF therapy...
  45. Cohen B, Sachar D. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505 pubmed publisher
    ..New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed. ..
  46. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, et al. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol. 2012;41:490-1 pubmed publisher
  47. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017;17:879-886 pubmed publisher
    Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis...
  48. Bach H, Rosenfeld G, Bressler B. Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins. J Crohns Colitis. 2012;6:628-9 pubmed publisher
  49. Kaltsonoudis E, Zikou A, Voulgari P, Konitsiotis S, Argyropoulou M, Drosos A. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125 pubmed publisher
    ..The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis factor (TNF) ? antagonists...
  50. Markusse I, de Vries Bouwstra J, Han K, van der Lubbe P, Schouffoer A, Kerstens P, et al. Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Res Ther. 2014;16:430 pubmed publisher
    ..The choice of treatment strategy should depend more on rapid relief of symptoms than on prognostic factors. Netherlands Trial Register NTR262 (registered 7 September 2005) and NTR265 (8 September 2005). ..
  51. Scheinberg M, Castaneda Hernandez G. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther. 2014;16:501 pubmed publisher
    ..This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology. ..
  52. Otake H, Matsumoto S, Mashima H. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study. Medicine (Baltimore). 2017;96:e6635 pubmed publisher
    ..CD patients, 68 continuously receiving the same biologic type for at least 1 year were divided into 2 groups: infliximab (IFX) (n?=?39) and adalimumab (ADA) (n?=?29)...
  53. Tanaka M, Sakai R, Koike R, Harigai M. Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents. J Rheumatol. 2015;42:1726-8 pubmed publisher